Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review

Affymax Inc. surged the most in 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.